Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Rituximab in Participants With Refractory Large B-Cell Lymphoma

Completed · Phase 2

Conditions studied: Refractory Large B-cell Lymphoma

In brief

The primary objective of this study is to estimate the efficacy of axicabtagene ciloleucel in combination with rituximab, as measured by assessment of response rates in adult participants with relapsed/refractory large B-cell lymphoma.

Key facts

Study ID

NCT04002401

Run by

Kite, A Gilead Company

People needed

27

Starts

2019-11-05

Expected to finish

2023-01-30

Last updated by the study team

2024-02-20

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Banner MD Anderson Cancer Center — Gilbert, Arizona, United States
• City of Hope National Medical Center — Duarte, California, United States
• Stanford Cancer Institute — Palo Alto, California, United States
• UCLA Hematology/Oncology — Santa Monica, California, United States
• Mayo Clinic Florida — Jacksonville, Florida, United States
• University of Chicago Medical Center — Chicago, Illinois, United States
• Loyola University Medical Center — Maywood, Illinois, United States
• Mayo Clinic — Rochester, Minnesota, United States
• John Theurer Cancer Center at Hackensack University Medical Center — Hackensack, New Jersey, United States
• Columbia University Medical Center, New York Presbyterian Hospital — New York, New York, United States
• Vanderbilt University Medical Center — Nashville, Tennessee, United States
• St. David's South Austin Medical Center — Austin, Texas, United States
• The University of Texas MD Anderson Cancer Center — Houston, Texas, United States
• Swedish Cancer Institute — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.